|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.70 CNY | -0.87% |
|
+0.06% | -11.55% |
| 12-08 | Betta Pharmaceuticals's Four Drugs Placed on China's Insurance Drug List | MT |
| 11-03 | Betta Pharmaceuticals Gets Distribution Rights for Hemophilia Drug | MT |
| Capitalization | 20.07B 2.84B 2.42B 2.26B 2.13B 3.92B 258B 4.28B 26.42B 10.25B 121B 10.67B 10.45B 443B | P/E ratio 2025 * |
35.2x | P/E ratio 2026 * | 24x |
|---|---|---|---|---|---|
| Enterprise value | 21.47B 3.04B 2.59B 2.42B 2.28B 4.19B 276B 4.58B 28.26B 10.96B 130B 11.42B 11.18B 474B | EV / Sales 2025 * |
5.97x | EV / Sales 2026 * | 4.96x |
| Free-Float |
51.51% | Yield 2025 * |
0.75% | Yield 2026 * | 0.96% |
| 1 day | -0.87% | ||
| 1 week | +0.06% | ||
| Current month | -2.95% | ||
| 1 month | -12.44% | ||
| 3 months | -32.56% | ||
| 6 months | -24.68% | ||
| Current year | -11.55% |
| 1 week | 47.15 |  | 49.32 |
| 1 month | 46.51 | | 54.36 |
| Current year | 46.51 | | 79.8 |
| 1 year | 46.51 | | 79.8 |
| 3 years | 30.43 | | 79.8 |
| 5 years | 30.43 | | 143.59 |
| 10 years | 23.19 | | 160.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lie Ming Ding
CEO | Chief Executive Officer | 61 | 22/08/2013 |
Jian Xun Fan
DFI | Director of Finance/CFO | 54 | 30/03/2017 |
Mao Li
CTO | Chief Tech/Sci/R&D Officer | 68 | 31/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Lie Ming Ding
CHM | Chairman | 61 | 22/08/2013 |
Jia Tong
BRD | Director/Board Member | 48 | 21/01/2021 |
Jiang Wan
BRD | Director/Board Member | 56 | 15/03/2017 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.36% | 0 M€ | -19.71% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.87% | +0.06% | -12.77% | -6.82% | 2.84B | |
| -0.38% | -1.86% | -16.12% | -36.55% | 60.15B | |
| +1.03% | +0.41% | +5.82% | -17.63% | 8.58B | |
| +0.50% | -1.77% | +29.60% | +5.55% | 7.32B | |
| -1.84% | -0.60% | +25.78% | +79.03% | 7.06B | |
| +0.86% | -0.26% | -2.34% | +116.07% | 5.91B | |
| -0.64% | +1.25% | +207.35% | +61.64% | 4.44B | |
| +1.40% | +3.24% | +30.38% | +33.60% | 2.7B | |
| +0.87% | -1.80% | +19.19% | +45.66% | 2.5B | |
| +0.10% | -0.77% | -16.39% | +1.49% | 1.95B | |
| Average | +0.10% | -0.16% | +27.05% | +28.20% | 10.35B | |
| Weighted average by Cap. | -0.17% | -1.18% | +4.33% | -5.83% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.59B 509M 434M 405M 381M 702M 46.15B 767M 4.73B 1.84B 21.75B 1.91B 1.87B 79.36B | 4.31B 610M 520M 486M 457M 841M 55.28B 919M 5.67B 2.2B 26.06B 2.29B 2.24B 95.08B |
| Net income | 571M 80.98M 68.99M 64.44M 60.63M 112M 7.33B 122M 752M 292M 3.46B 304M 297M 12.61B | 812M 115M 98.01M 91.55M 86.14M 159M 10.42B 173M 1.07B 415M 4.91B 432M 423M 17.92B |
| Net Debt | 1.4B 198M 169M 158M 148M 273M 17.96B 299M 1.84B 715M 8.47B 744M 728M 30.89B | 1.28B 182M 155M 145M 136M 251M 16.48B 274M 1.69B 655M 7.77B 683M 668M 28.33B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 47.70 ¥ | -0.87% | 5,558,739 |
| 11/12/25 | 48.12 ¥ | -1.01% | 4,469,670 |
| 10/12/25 | 48.61 ¥ | +0.79% | 4,989,949 |
| 09/12/25 | 48.23 ¥ | -0.06% | 5,919,159 |
| 08/12/25 | 48.26 ¥ | +1.24% | 6,104,391 |
End-of-day quote Shenzhen S.E., December 11, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300558 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition